We are live on ! Find out more

Apyx Medical

APYX

Market cap $110M

2.61 USD

+0.11

4.4%

At close Updated Oct 28, 4:00 PM EDT

Pre-market

After hours

2.56

-0.05

1.92%

1 day

4.4%

5 days

6.1%

1 month

4.4%

3 months

-32.38%

6 months

-28.88%

Year to date

-25.43%

1 year

-15.81%

5 years

-81.55%

10 years

-52.97%

About: Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Surgical Aesthetics and Original Equipment Manufacturing (OEM). Its Surgical Aesthetics segment derives the majority of its revenue.

Employees: 205

Healthcare Medical Devices

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 11.1%

Neutral 88.9%

Negative 0%

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Apyx Medical Corporation (NASDAQ: APYX)

NEW YORK, Oct. 22, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Apyx Medical Corporation (NASDAQ: APYX) on behalf of the company's shareholders. The investigation seeks to determine whether Apyx Medical Corporation's directors breached their fiduciary duties in connection with recent corporate actions.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Apyx Medical Corporation (NASDAQ: APYX)

Apyx Medical Corporation to Release Third Quarter of Fiscal Year 2026 Financial Results on November 5, 2026

CLEARWATER, Fla., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that its financial results for the third quarter of fiscal year 2026 will be released before markets open on Thursday, November 5th.

Apyx Medical Corporation to Release Third Quarter of Fiscal Year 2026 Financial Results on November 5, 2026

Apyx Medical Corporation to Participate in Upcoming Investor Conferences

CLEARWATER, Fla., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that management will present at the following investor conferences: UBS Global Healthcare Conference – November 9-11, 2026 (Miami, FL) Management will participate in a fireside chat at 10:15am ET and will host one-on-one meetings with investors on Monday, November 9.

Apyx Medical Corporation to Participate in Upcoming Investor Conferences

Apyx Medical Announces New Clinical Study Demonstrating Renuvion®'s Impact on Skin Quality

CLEARWATER, Fla., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical” or the “Company”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced results from a prospective clinical study evaluating the effects of Renuvion helium plasma radiofrequency technology on biological markers of skin quality.

Apyx Medical Announces New Clinical Study Demonstrating Renuvion®'s Impact on Skin Quality

Apyx Medical Sees GLP-1 Boom Fueling Demand for Renuvion, AYON Body Contouring

Apyx Medical NASDAQ: APYX is positioning its Renuvion technology and newly launched AYON Body Contouring System to address growing demand for surgical aesthetic procedures, a trend CEO Charlie Goodwin said has been reshaped by the increasing use of GLP-1 weight-loss drugs.

Apyx Medical Sees GLP-1 Boom Fueling Demand for Renuvion, AYON Body Contouring

Apyx Medical Corporation (APYX) Q2 2026 Earnings Call Transcript

Apyx Medical Corporation (APYX) Q2 2026 Earnings Call Transcript

Apyx Medical Corporation (APYX) Q2 2026 Earnings Call Transcript

Zacks Investment Research

Apyx Medical (APYX) Reports Q2 Loss, Beats Revenue Estimates

Apyx Medical (APYX) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.09 per share a year ago.

Apyx Medical (APYX) Reports Q2 Loss, Beats Revenue Estimates

Apyx Medical Q2 Earnings Call Highlights

Apyx Medical NASDAQ: APYX reported second-quarter revenue growth of 22% as sales in its surgical aesthetics business increased, led by adoption of its AYON Body Contouring System, international generator sales and domestic demand for single-use handpieces.

Apyx Medical Q2 Earnings Call Highlights

Apyx Medical Corporation Reports Second Quarter 2026 Financial Results

CLEARWATER, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today reported financial results for its second quarter ended June 30, 2026.

Apyx Medical Corporation Reports Second Quarter 2026 Financial Results

Apyx Medical Corporation to Participate in the Canaccord Genuity 46th Annual Growth Conference

CLEARWATER, Fla., July 28, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that management will participate in the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, in Boston, MA.

Apyx Medical Corporation to Participate in the Canaccord Genuity 46th Annual Growth Conference

See News Rankings

Price charts implemented using Lightweight Charts™